Phio Pharmaceuticals Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Phio Pharmaceuticals Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | Mar 25, 2021 |
| FY2020 | Dec 31, 2019 | $21.0K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $138.0K | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $15.0K | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $19.0K | Mar 26, 2018 |
| FY2016 | Dec 31, 2015 | $34.0K | Mar 30, 2017 |
| FY2013 | Dec 31, 2013 | $399.0K | Mar 28, 2014 |
| FY2013 | Dec 31, 2012 | $97.0K | Mar 28, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.70M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($7.15M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($10.83M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($11.48M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($13.29M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($8.79M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($8.91M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($7.36M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($12.45M) | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | ($8.99M) | Mar 26, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.22M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($7.39M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($10.82M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($11.46M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($13.51M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($8.79M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($8.99M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($7.36M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($14.06M) | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | ($9.02M) | Mar 26, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.62M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $3.64M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $6.33M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $7.01M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $8.89M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $3.72M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $4.30M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $4.33M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $5.37M | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $5.42M | Mar 26, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.98M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($7.11M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($10.75M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($12.13M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($11.86M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($8.80M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($8.65M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($7.52M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($9.51M) | Mar 27, 2019 |
| FY2013 | Dec 31, 2013 | ($6.31M) | Mar 28, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.0K | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $1.0K | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $5.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $121.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $51.0K | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $19.0K | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $72.0K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $5.0K | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $203.0K | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $4.0K | Mar 26, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.49M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $5.74M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $9.36M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $12.81M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $25.17M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $15.74M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $8.04M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $15.32M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $4.10M | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $13.40M | Mar 26, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.34M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $1.02M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $1.63M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.97M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.24M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $2.72M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $2.29M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.74M | Mar 26, 2020 |
| FY2013 | Dec 31, 2013 | $2.08M | Mar 28, 2014 |
| FY2013 | Dec 31, 2012 | $1.71M | Mar 28, 2014 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.15M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $4.72M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $7.73M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $10.84M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $21.93M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $13.02M | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | $5.75M | Mar 22, 2022 |
| FY2020 | Dec 31, 2018 | $13.58M | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $1.83M | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | $10.86M | Mar 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($155.05M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($146.36M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($139.21M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($128.38M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($116.90M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($103.61M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($94.82M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($85.91M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($78.55M) | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | ($66.10M) | Mar 26, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.03M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $5.38M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $8.49M | Mar 31, 2025 |
| FY2017 | Dec 31, 2017 | $3.58M | Mar 26, 2018 |
| FY2017 | Dec 31, 2016 | $12.91M | Mar 26, 2018 |
| FY2016 | Dec 31, 2015 | $5.12M | Mar 30, 2017 |
| FY2016 | Dec 31, 2014 | $8.50M | Mar 30, 2017 |
| FY2015 | Dec 31, 2013 | $11.39M | Mar 30, 2016 |
| FY2014 | Dec 31, 2012 | $5.13M | Mar 30, 2015 |
| FY2013 | Dec 31, 2011 | $503.0K | Mar 28, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | (9) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | (46) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (10) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (12) | Mar 22, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (9) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | (46) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (10) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (12) | Mar 22, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11.62M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 1.73M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 416,368 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 1.14M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 1.13M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | 5.78M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | 669,433 | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 342,578 | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | 2.43M | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | 1.30M | Mar 26, 2018 |